Alvotech (ALVO) to Release Earnings on Wednesday

Alvotech (NASDAQ:ALVO) is expected to be posting its quarterly earnings results after the market closes on Wednesday, March 26th. Analysts expect Alvotech to post earnings of ($0.74) per share and revenue of $97.99 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Alvotech Stock Up 0.2 %

Alvotech stock opened at $11.57 on Monday. Alvotech has a 52 week low of $9.15 and a 52 week high of $14.76. The business has a 50-day simple moving average of $12.20 and a 200 day simple moving average of $12.18. The stock has a market cap of $3.49 billion, a price-to-earnings ratio of -6.25 and a beta of -0.16.

Wall Street Analysts Forecast Growth

Separately, UBS Group assumed coverage on Alvotech in a research report on Friday, February 14th. They set a “buy” rating and a $18.00 target price for the company.

Alvotech Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.